marked.bio

YES1/SRC inhibitor · small molecule

NXP900

3 active trials across 3 of our biomarkers, targeting YES1/SRC. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 1
EGFR exon 19 deletion / L858R 1 1 Phase 1
IDH1/2 mutation 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of NXP900.

  1. Nuvectis Pharma 3

Trials

3 of 3 trials shown

  1. Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

    Recruiting Phase 1 Nuvectis Pharma Started 2026Primary completion 2027-08 NCT07784959

    NXP900lorlatinib FDA EU

    Unresectable, metastatic or locally advanced ALK-positive NSCLC.

    ALK fusionALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma

  2. Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting Phase 1 Nuvectis Pharma Started 2025Primary completion 2026-12 NCT07315113

    NXP900osimertinib FDA EU

    Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.

    EGFR exon 19 deletion / L858REGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients

  3. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

    Active, not recruiting Phase 1 Nuvectis Pharma Started 2023Primary completion 2027-03 NCT05873686

    NXP900

    …gene mutation or TYMS, YAP1, YES1, or TAZ1 gene amplification, or cholangiocarcinoma with IDH1 or IDH2 mutations.

    IDH1/2 mutationAdvanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma